Register entry
Douglas Pharmaceuticals America Limited
- Registered sites
- 1
- Drug products
- 2
- Live patents
- 1
- Countries
- 1
- Base
- New Zealand
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingLabellingFinished drug manufacturePackagingRelabellingRepackaging
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Douglas Manufacturing Limited | Lincoln AucklandNew Zealand | Analytical testing, Labelling, Finished drug manufacture, Packaging, Relabelling, Repackaging | 3005641565 |
Exclusivity
Patents
1Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| VERSACLOZ | CLOZAPINE | May 2028 |
Catalogue
Marketed products
2Showing 2 of 2.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| - | Norethindrone Acetate And Ethinyl Estradiol Capsules And Ferrous Fumarate Capsules, 1 MG/20 MCG | CAPSULE | DRUG FOR FURTHER PROCESSING |
| - | Norethindrone Acetate And Ethinyl Estradiol Capsules And Ferrous Fumarate Capsules, 1 MG/20 MCG | CAPSULE | DRUG FOR FURTHER PROCESSING |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.